Israeli acute heart failure (HF) therapy firm Magenta Medical Ltd. has bulked up its coffers with an additional $15m, following a Series B financing that brought in new investors from Japan and the clinical cardiovascular community.
Series B Pumps $15m Into Abiomed-Backed Acute HF Start-Up
Magenta Medical Ltd, an Israeli start-up founded by cardiology veterans and backed by miniaturized heart pump specialist Abiomed, has reeled in $15m in Series B financing. The additional capital will enable the company to take its catheter-based therapy for acute heart failure through clinical trials and beyond CE-mark approval.